Capecitabine is an effective treatment in gemcitabine-refractory advanced pancreatic cancer

被引：0
|
作者：
Arrazubi, V [1 ]
Illarramendi, J. [1 ]
Lainez, N. [1 ]
Salgado, E. [1 ]
Martinez, M. [1 ]
Amillano, K. [1 ]
Vera, R. [1 ]
机构：
[1] Hosp Navarra, Pamplona, Spain
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：75 / 75
页数：1
相关论文
共 50 条
  • [21] Impact of S-1 in Patients with Gemcitabine-refractory Pancreatic Cancer in Japan
    Nakai, Yousuke
    Isayama, Hiroyuki
    Sasaki, Takashi
    Sasahira, Naoki
    Kogure, Hirofumi
    Hirano, Kenji
    Tsujino, Takeshi
    Ijichi, Hideaki
    Tateishi, Keisuke
    Tada, Minoru
    Omata, Masao
    Koike, Kazuhiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (08) : 774 - 780
  • [22] Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
    Wolpin, Brian M.
    Hezel, Aram F.
    Abrams, Thomas
    Blaszkowsky, Lawrence S.
    Meyerhardt, Jeffrey A.
    Chan, Jennifer A.
    Enzinger, Peter C.
    Allen, Brittany
    Clark, Jeffrey W.
    Ryan, David P.
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (02) : 193 - 198
  • [23] Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer
    Villa, Eugenio
    Cereda, Stefano
    Mazza, Elena
    Vigano, Maria Grazia
    Vitali, Giordano
    Rognone, Alessia
    Di Carlo, Valerio
    Reni, Michele
    ANNALS OF ONCOLOGY, 2007, 18 : 15 - 15
  • [24] Multicenter phase. trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
    Chung, Moon Jae
    Kang, Huapyong
    Kim, Ho Gak
    Hyun, Jong Jin
    Lee, Jun Kyu
    Lee, Kwang Hyuck
    Noh, Myung Hwan
    Kang, Dae Hwan
    Lee, Sang Hyub
    Bang, Seungmin
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 10 (12) : 505 - 515
  • [25] Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer
    Cereda, S.
    Mazza, E.
    Vigano, M.
    Passoni, P.
    Balzano, G.
    Zerbi, A.
    Staudacher, C.
    di Carlo, V.
    Reni, M.
    ANNALS OF ONCOLOGY, 2007, 18 : VII113 - VII113
  • [26] Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer
    Cereda, S.
    Reni, M.
    JOURNAL OF CHEMOTHERAPY, 2008, 20 (04) : 509 - 512
  • [27] A phase II study of docetaxel (D) followed by flavopiridol (F) in advanced, gemcitabine-refractory pancreatic cancer (PC)
    Carvajal, R. D.
    Shah, M. A.
    Tse, A.
    Lefkowitz, R.
    Kelsen, D. P.
    Schwartz, G. K.
    O'Reilly, E. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Salvage chemotherapy of fixed dose rate gemcitabine and S-1 combination therapy (FGS) for gemcitabine-refractory advanced pancreatic cancer
    Kasuga, A.
    Okano, N.
    Naruge, D.
    Kitamura, H.
    Takasu, A.
    Nagashima, F.
    Furuse, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S633 - S634
  • [29] Gemcitabine plus capecitabine in elderly patients with advanced pancreatic cancer
    Vasiliki, Michalaki
    Andreas, Poydorou
    Antonios, Vezakis
    Georgios, Frangulidis
    Theodosios, Theodosopoulos
    Christos, Papadimitriou
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] Phase II study of PHY906 plus capecitabine (CAP) in pts with gemcitabine-refractory pancreatic cancer (PC) and measurement of cytokines
    Seif, M.
    Li, J.
    Lamb, L.
    Kiley, K.
    Bussom, S.
    Carbone, R.
    Elligers, K.
    Krishnamoorthy, S.
    Liu, S.
    Cheng, Y. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345